GeneCentric Therapeutics CEO and Founder Dr. Myla-Lai Goldman to be featured on ”Radio In Vivo: Your Link to the Triangle Science Community!” November 1, 2017
Discussing the latest advances in Precision Medicine approaches to Treat and Pursue Cures for Cancer
Durham, NC, November 1 , 2017 – GeneCentric Therapeutics Founder and CEO, Dr. Myla-Lai Goldman, will be featured today on the radio show ”Radio In Vivo: Your Link to the Triangle Science Community!”, from 11:00am-12:00pm, ET, on WCOM – FM103.5, based in Carrboro, NC., and available via webstream at: https://radioinvivo.org/2017/11/01/genecentric-therapeutics/ as well as at the show’s website: http://radioinvivo.net.
Dr. Goldman will discuss some of the latest advances in unmasking the complexities of the different types of cancer that are enabling the development of precision medicines in order to improve outcomes for patients as well as support efforts toward attaining cures. New treatment approaches such as immuno-therapy are changing the therapeutic landscape for cancer treatments, producing dramatic improvements in long term survival rates compared with conventional chemotherapy, but only in subsets of patients. Pronounced effects, seen in small numbers of study participants, suggest that prospectively identifying ‘responders’ could result in greater clinical development success for new therapies, expanded uses for existing drugs, and better results for patients. As part of the discussion, Dr. Goldman will describe GeneCentric’s focus in advancing these efforts to ‘de-code’ tumor biology by combining gene expression data with disease-related molecular pathways and immune cell expression through advanced computational biology technologies.
GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable development of precision medicine drugs and improve patient outcomes. Our approach applies the Cancer Subtype Platform (CSP®) to parse complex tumor biology into genomic signatures revealing high-resolution cancer subtypes, with potential as universal biomarkers for susceptibility to multiple classes of agents including immune-based, molecularly targeted and chemotherapeutics. We are commercializing our technology through strategic collaborations with pharmaceutical and biotech companies to define responder populations applicable throughout the drug development cycle. GeneCentric has established several pharmaceutical collaborations, including an alliance with Bristol Myers Squibb in immuno-oncology. For more information, please visit www.genecentric.com.
About Radio In Vivo
Radio In Vivo is a weekly science interview radio program that airs Wednesdays at 11AM on community radio station WCOM-FM 103.5 in Carrboro, NC. We feature in-depth interviews with the researchers who make the Research Triangle of North Carolina one of the world’s leading hubs of scientific research and development. All this is made possible by community support, including our underwriters. A full archive of past programs is available here, and download links for past shows up to November 2011 can be found at Radio In Vivo’s previous archive . Listen live online at http://wcomfm.org/
GeneCentric Therapeutics, Inc
Walter Capone, 984-329-3837
Chief Business Officer